Biotechnology

Outlook Therapeutics

Outlook Therapeutics Wins FDA Appeal, Plans June Resubmission of LYTENAVA BLA

Outlook Therapeutics released FY2026 Q2 earnings on May 15 (EST), actual revenue USD 127.44 K (forecast USD 4.4 M), actual EPS USD -0.0544 (forecast USD -0.11)

Outlook Therapeutics released FY2026 Semi-Annual Earnings on May 15 EST, with actual revenue of USD -1.08 M and EPS of USD -0.388

Outlook Therapeutics released FY2026 Q1 earnings on February 17 (EST), actual revenue USD -1.208 M (forecast USD 3.138 M), actual EPS USD -0.3829 (forecast USD -0.2033)

Outlook Therapeutics released FY2025 Q4 earnings on December 19 (EST), actual revenue USD -92.32K (forecast USD 5.846M), actual EPS USD -0.2816 (forecast USD -0.2775)

Outlook Therapeutics released FY2025 Annual Earnings on December 19 (EST), actual revenue USD 1.414 M (forecast USD 6.719 M), actual EPS USD -1.794 (forecast USD -1.6425)

Douglas Tsao Maintains Hold Rating on Outlook Therapeutics

Outlook Therapeutics Completes Type A Meeting with FDA

Outlook Therapeutics released FY2025 9 Months Earnings on August 14 EST, with actual revenue of USD 1.505 M and EPS of USD -1.3343

Outlook Therapeutics released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 1.505 M (forecast USD 1.663 M), actual EPS USD -0.5499 (forecast USD -0.3525)

Outlook Therapeutics Appoints Bob Jahr as CEO

Outlook Therapeutics Launches First Bevacizumab Ophthalmic Formulation in Germany and the UK

Outlook Therapeutics Plans Public Offering of Common Stock and Warrants

Outlook Therapeutics released FY2025 Q2 earnings on May 15 (EST), actual revenue USD 0 (forecast USD 702.6 K), actual EPS USD -1.5014 (forecast USD -0.542)

Outlook Therapeutics released FY2025 Semi-Annual Earnings on May 15 EST, with actual revenue USD 0 and actual EPS USD -1.0531

Outlook Therapeutics Plans to Launch LYTENAVA™ for Wet AMD Treatment

Outlook Therapeutics Inc forecasts Q1 2025 EPS loss of 60 cents

Outlook Therapeutics, Inc. announces FDA acceptance of BLA for ONS-5010, review expected by August 27, 2025

HC Wainwright Lowers Outlook Therapeutics' EPS Estimate for Q2 2025 to ($0.60)

Outlook Therapeutics released FY2025 Q1 earnings on February 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS 0.717 USD (forecast -0.6166 USD)

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

ELMT

Lennar Corp shares fell 2.7% in pre-market trading after reporting mixed Q2 results: adjusted EPS of $1.31 beat estimates, but revenue of $7.94 billion missed the $8.02 billion forecast. The stock dropped to $92.35. Other notable decliners included Adobe (down 4.7% despite raised guidance and CFO departure), Richtech Robotics, Elmet Group, Alamar Biosciences, AIFU, Zenas Biopharma, Gloo Holdings, OIO Group, and MBX Biosciences.

- U.S. stock futures rose this morning, with Dow futures increasing by around 300 points on Friday.  
- Lennar Corp reported mixed second-quarter results, with adjusted earnings of $1.31 per share surpassing estimates, but revenue of $7.94 billion missed forecasts, causing shares to drop 2.7% in pre-market trading.  
- Other stocks, including Richtech Robotics and Elmet Group, also saw declines, while Adobe's shares fell despite positive financial results and a change in CFO.

benzinga_article

MBX Biosciences

Richtech Robotics - B

Elmet

Lennar-B Shares

Adobe

Lennar

Alamar Biosciences

Gloo

Zenas Biopharma

AIFU

Leverage Shares 2X Long ADBE Daily ETF

Direxion Daily ADBE Bull 2X ETF

Dow Jones Industrial Average

OIO GROUP C/WTS 02/08/2028 (TO PUR COM)

Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session

RGNT

INDP

ADTX

OTLK

During Wednesday's intraday session, several healthcare stocks experienced significant volatility. Gainers included Indaptus Therapeutics (+20.4%), Outlook Therapeutics (+19.9%), and Myomo (+19.84%). Conversely, major losers featured Picard Medical (-32.4%), Aditxt (-31.15%), and Regentis Biomaterials (-29.4%). The list highlights substantial price movements across various market capitalizations in the health care sector.

Picard Medical

Regentis Biomaterials

Indaptus Therapeutics

Myomo

Aditxt

Clover Health Investments

ENvue Medical

Shoulder Innovations

Silexion Therapeutics

CervoMed

Aptorum

SILEXION THERAPEUTICS CORP C/WTS EXP 15/08/2029 (TO PUR COM)

12 Health Care Stocks Moving In Wednesday's Intraday Session

HOOD

Insider buying reports for Tuesday, June 2 highlight significant purchases at Robinhood Markets (HOOD) and Outlook Therapeutics (OTLK). Robinhood Director Meyer Malka bought 249,000 shares for $20.02M, currently up 11%. Outlook Therapeutics executive Ghiath M. Sukhtian purchased over 8.5 million shares for $5M, seeing a 56.1% gain based on recent highs.

nasdaq

Robinhood

Nasdaq

Tuesday 6/2 Insider Buying Report: HOOD, OTLK

Outlook Therapeutics announced the resubmission of its Biologics License Application (BLA) to the U.S. FDA for ONS-5010/LYTENAVA™, an ophthalmic formulation of bevacizumab for treating neovascular age-related macular degeneration (nAMD). This follows a successful appeal against a previous Complete Response Letter, with the FDA confirming substantial evidence of effectiveness. The resubmission is classified as Class 1, with a PDUFA decision expected within 60 days.

StockTitan

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg) | OTLK Stock News

SBIO

IBBQ

LABD

Outlook Therapeutics completed a registered direct offering, selling approximately 8.54 million common shares to GMS Ventures and Investments. The transaction was executed under a securities purchase agreement dated May 28, 2026, utilizing the company's effective Form S-3 registration statement. This event is classified as corporate finance related information.

TradingView

iShares Biotechnology ETF

VG Health

SPDR S&P Biotech

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

Proshares UltraShort Nasdaq Biotech

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bear 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Outlook Therapeutics sells 8.54M shares in registered direct offering to GMS Ventures

Outlook Therapeutics, Inc. has priced a $5 million registered direct offering of 8,539,709 shares at $0.5855 each to its largest stockholder, GMS Ventures. The offering is expected to close around May 29, 2026, and aims to raise funds for working capital. Additionally, the company will amend existing warrants held by GMS Ventures. Outlook Therapeutics is developing an investigational treatment for retinal diseases. The stock closed at $0.74, up 26.39%.

Outlook Therapeutics Prices $5 Million Registered Direct Offering

AKTX

CODX

SciSparc (SPRC) gained regulatory approval to acquire a 54% stake in CliniQuantum, boosting its shares by nearly 140%. Co-Diagnostics (CODX) rallied over 50% for the third consecutive day amid Ebola outbreak developments. Akari Therapeutics (AKTX) shares rose 38.46% following positive preclinical data. Outlook Therapeutics (OTLK) jumped 25% as it prepares to resubmit its biologics license application. Polaryx Therapeutics (PLYX) closed a $10 million PIPE financing.

rttnews

Akari Therap

Co-Diagnostics

iShares Genomics Immunology and Healthcare ETF

SciSparc

Fortrea

Tevogen Bio

MiNK Therapeutics

Polaryx Therapeutics

TEVOGEN BIO HOLDINGS INC C/WTS 14/02/2029 (TO PUR COM)

Top Biotech Gainers: SPRC Deal Gets Nod, CODX Rallies, OTLK, AKTX, FTRE Drawing Investor Interest

Outlook Therapeutics(OTLK.US)